Latest News and Press Releases

Refund based on AUD$2.8 million in eligible R&D spending used to advance the Company’s development programs.Two nutraceutical products currently being prepared for US launch by end of 2016. ...

MELBOURNE, Australia, May 02, 2016 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, an Australian private company, today announced positive top-line results of an independent early-phase US clinical...

MELBOURNE, Australia, March 08, 2016 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals Pty. Ltd., a privately-held company commercializing evidence-based nutraceuticals and pharmaceuticals, has secured a...

MELBOURNE, Australia, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, an Australian nutraceutical and pharmaceutical company, is pleased to announce a collaborative research agreement...

MELBOURNE, Australia, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, an Australian company developing evidence-based nutraceuticals and pharmaceuticals, today announced it has entered...

MELBOURNE, Australia, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, an Australian company developing evidence-based nutraceuticals and pharmaceuticals, is pleased to announce its...

Chairman Fred Nadjarian retires from Board to assume role as Scientific Advisor. Secures R&D loan facility through Metamor Capital Partners. Preparing for US market entry with first...

MELBOURNE, Australia, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, a privately held Australian company commercializing tocotrienol-based nutraceuticals and pharmaceuticals, has appointed...

MELBOURNE, Australia, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, an Australian private company commercializing evidence-based nutraceuticals and pharmaceuticals based on...

Primary endpoints of Phase I Single Ascending Dose pharmacokinetic study achieved Bioavailability of Gordagen's MELT3TM formulation confirmed, with good plasma levels obtained Dose...